Clinical stages of recurrent hepatocellular carcinoma: A retrospective cohort study.

World J Clin Cases

Department of Hepatobiliary-Pancreatic-Splenic Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi Zhuang Autonomous Region, China.

Published: September 2021

Background: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and has relatively high recurrence rates. Few studies have been published on the clinical stages of recurrent HCC.

Aim: To assess the applicability of the Barcelona Clinic Liver Cancer (BCLC) staging for recurrent HCC and the need to establish clinical stage criteria for recurrent HCC.

Methods: The clinicopathological data of 81 patients with recurrent HCC who were admitted to the Hospital of Guangxi Zhuang Autonomous Region from January 2013 to December 2017 were collected. The patients were divided into three groups according to the BCLC staging system as follows: (1) Group A with BCLC stage A, 51 patients; (2) Group B with BCLC stage B, 14 patients; and (3) Group C with BCLC stage C, 16 patients. The median time to tumor recurrence and the median overall survival were compared.

Results: The median time to tumor recurrence in groups A, B, and C was 16 ± 1.5 mo, 10 ± 2.8 mo, and 6 ± 0.5 mo, respectively, with a statistically significant difference among them ( = 70.144, < 0.05); no statistically significant difference was noted between group A and group B ( = 2.659, > 0.05), although there were statistically significant differences between group A and group C and between group B and group C ( = 62.110, and 19.972, < 0.05). The median overall survival in groups A, B, and C were 42 ± 5.1 mo, 22 ± 3.1 mo, and 13 ± 1.8 mo, respectively, with a statistically significant difference among them ( = 38.949, < 0.05); there were statistically significant differences between group A and group B, group A and group C, and group B and group C ( = 9.577, 37.172, and 7.183, respectively; < 0.05).

Conclusion: There are different prognoses in recurrent HCC patients according to the BCLC staging. Therefore, BCLC staging is applicable to recurrent HCC and it is essential to formulate clinical stage criteria for recurrent HCC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462222PMC
http://dx.doi.org/10.12998/wjcc.v9.i27.8020DOI Listing

Publication Analysis

Top Keywords

group group
36
recurrent hcc
20
bclc staging
16
group
15
group bclc
12
bclc stage
12
stage patients
12
statistically difference
12
005 statistically
12
clinical stages
8

Similar Publications

Affinity descriptor of metal catalysts: concept, measurement and application of oxygen affinity in the catalytic transformation of oxygenates.

Chem Soc Rev

January 2025

National-local Joint Engineering Research Center of Biomass Refining and High-quality Utilization, Changzhou University, Changzhou 213164, China.

Multiple oxygenate groups in biomass-based feedstocks are open to multiple catalytic pathways and products, typically resulting in low selectivity for the desired products. In this context, strategies for rational catalyst design are critical to obtain high selectivity for the desired products in biomass upgrading. The Sabatier principle provides a conceptual framework for designing optimal catalysts by following the volcanic relationship between catalyst activity for a reaction and the binding strength of a substrate on a catalyst.

View Article and Find Full Text PDF

Purpose: This cross-sectional study explored how the speechreading ability of adults with hearing impairment (HI) in China would affect their perception of the four Mandarin Chinese lexical tones: high (Tone 1), rising (Tone 2), falling-rising (Tone 3), and falling (Tone 4). We predicted that higher speechreading ability would result in better tone performance and that accuracy would vary among individual tones.

Method: A total of 136 young adults with HI (ages 18-25 years) in China participated in the study and completed Chinese speechreading and tone awareness tests.

View Article and Find Full Text PDF

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents.

Hum Vaccin Immunother

December 2025

Research and Development, Infectious Disease, Moderna, Inc., Cambridge, MA, USA.

Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12-17 years), with and without pre-booster SARS-CoV-2 infection. Participants who had received the 2-dose mRNA-1273 100-µg primary series in the TeenCOVE trial (NCT04649151) were offered the mRNA-1273 50-μg booster. Primary objectives included safety and inference of effectiveness by establishing noninferiority of neutralizing antibody (nAb) responses after the booster compared with the nAb post-primary series of mRNA-1273 among young adults in COVE (NCT04470427).

View Article and Find Full Text PDF

Methyleugenol (ME) has been classified as a "group 2B carcinogen" by IARC. Its positional isomer methylisoeugenol (MIE) has been considered to be of "generally recognized as safe'' status by FDA. ME was more cytotoxic than MIE in cultured mouse primary hepatocytes.

View Article and Find Full Text PDF

Objectives: In this study, the capacity of End-tidal carbon dioxide (EtCO2) levels to predict the risk of major cardiovascular events (MACE) in patients diagnosed with acute coronary syndrome and the relationship between risk scoring systems (TIMI, GRACE, HEART) and EtCO2 values were examined.

Methods: EtCO2 values of the patients in the study were measured with a capnography device. Each patient's MACE status was recorded.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!